Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review.

ABSTRACT:

Objective

Symptoms of depression and anxiety are common in neuroendocrine tumor (NET), yet controversy exists over whether serotonin-mediated antidepressants (SAs) are safe in this population. We sought to address this knowledge gap.

Method

Following PRISMA guidelines, we conducted a systematic review to identify NET patients who were prescribed SA.

Results

We identified 15 articles, reporting on 161 unique patients, 72 with carcinoid syndrome (CS) and 89 without. There was substantial agreement between reviewers at the full-text stage (κ = 0.69). Three of the articles, all with low risk of bias, accounted for most of the cases (149/161; 93%). Among the 72 NET patients with CS prior to antidepressant usage, CS was exacerbated in 6 cases (8%), only 3 (4%) of whom chose

SUBMITTER: Isenberg-Grzeda E 

PROVIDER: S-EPMC7416528 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature